Cargando…

Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) needs to be stratified for its heterogeneity. Oncogenic driver alterations such as EGFR mutation, ALK translocation, ROS1 translocation, and BRAF mutation predict response to treatment for LUAD. Since oncogenic driver alterations may modulate immune response in tumor micro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jian-Zhao, Gong, Chen, Xie, Zheng-Fu, Zhao, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876383/ https://www.ncbi.nlm.nih.gov/pubmed/33585210 http://dx.doi.org/10.3389/fonc.2020.593022

Ejemplares similares

Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
por: Shen, Yu-Jia, et al.
Publicado: (2021)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores
por: Xie, Hui, et al.
Publicado: (2021)

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors
por: Zhang, Runjiao, et al.
Publicado: (2021)

Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction
por: Lao, Yueqiong, et al.
Publicado: (2022)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
por: Han, Xiaohong, et al.
Publicado: (2019)

Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients
por: Liu, Di-Han, et al.
Publicado: (2019)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

A five-collagen-based risk model in lung adenocarcinoma: prognostic significance and immune landscape
por: Dong, Lingjun, et al.
Publicado: (2023)

Higher Levels of Pre-operative Peripheral Lymphocyte Count Is a Favorable Prognostic Factor for Patients With Stage I and II Rectal Cancer
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I and II Clear Cell Renal Cell Carcinomas
por: Shih, Andrew J., et al.
Publicado: (2020)

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution
por: Liu, Jun, et al.
Publicado: (2023)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

Preoperative prognostic prediction for stage I lung adenocarcinomas: Impact of the computed tomography features associated with the new histological grading system
por: Liang, Min, et al.
Publicado: (2023)

Radiotherapy for Stage I or II hypopharyngeal carcinoma
por: Nishimura, Hideki, et al.
Publicado: (2012)

Prognostic Value of Lymph Node Evaluation in Stage II Small Bowel Adenocarcinoma: An Updated Analysis of Surveillance, Epidemiology, and End Results Database
por: Liu, Zhen, et al.
Publicado: (2022)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer
por: Li, Qiaxuan, et al.
Publicado: (2021)

Prognostic value and immune infiltration of the gasdermin family in lung adenocarcinoma
por: Peng, Lu-Shan, et al.
Publicado: (2022)

Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma
por: Tian, Yiping, et al.
Publicado: (2022)

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
por: Yi, Lilan, et al.
Publicado: (2022)

Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma
por: Zhang, Yuan, et al.
Publicado: (2020)

Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma
por: Safaeian, Mahboobeh, et al.
Publicado: (2014)

Germline Predisposition and Copy Number Alteration in Pre-stage Lung Adenocarcinomas Presenting as Ground-Glass Nodules
por: Ren, Yijiu, et al.
Publicado: (2019)

LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
por: Guo, Wenhui, et al.
Publicado: (2021)

Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
por: Zhao, Zihuan, et al.
Publicado: (2020)

GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma
por: Han, Jiahui, et al.
Publicado: (2021)

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
por: Zhang, Yanwei, et al.
Publicado: (2020)

RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
por: Hao, Ruimin, et al.
Publicado: (2021)

Clinicopathological Features Combined With Immune Infiltration Could Well Distinguish Outcomes in Stage II and Stage III Colorectal Cancer: A Retrospective Study
por: Ren, Jiazi, et al.
Publicado: (2021)

Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma
por: Yin, Zhengrong, et al.
Publicado: (2022)

Prognostic scoring system based on eosinophil- and basophil-related markers for predicting the prognosis of patients with stage II and stage III colorectal cancer: a retrospective cohort study
por: Gao, Lijing, et al.
Publicado: (2023)

Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma
por: Cai, Lei, et al.
Publicado: (2021)

Phospholipid Phosphatase 4 as a Driver of Malignant Glioma and Pancreatic Adenocarcinoma
por: Tian, Wenxiu, et al.
Publicado: (2021)

Driver Gene Alterations in Malignant Progression of Gastric Cancer
por: Dong, Yuanqiang, et al.
Publicado: (2022)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment
por: Xu, Wen-Xiu, et al.
Publicado: (2020)

Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma
por: Hu, Junjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ki25dn6hqo74dfq1q5rfndtokn